<?xml version="1.0"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
<channel>
<title>BloggingStocks</title>
<link>http://www.bloggingstocks.com</link>
<description>BloggingStocks</description>
<image>
<url>http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif</url>
<title>BloggingStocks</title>
<link>http://www.bloggingstocks.com</link>
</image>
<language>en-us</language>
<copyright>Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only.</copyright>
<generator>Blogsmith http://www.blogsmith.com/</generator><item><title><![CDATA[GlaxoSmithKline Benefits from the Flu During the Fourth Quarter]]></title><link>http://www.bloggingstocks.com/2010/02/04/glaxosmithkline-benefits-from-the-flu-during-the-fourth-quarter/</link><guid isPermaLink="true">http://www.bloggingstocks.com/2010/02/04/glaxosmithkline-benefits-from-the-flu-during-the-fourth-quarter/</guid><comments>http://www.bloggingstocks.com/2010/02/04/glaxosmithkline-benefits-from-the-flu-during-the-fourth-quarter/#comments</comments><description><![CDATA[<p>Filed under: <a href="http://www.bloggingstocks.com/category/earnings-reports/" rel="tag">Earnings Reports</a></p><img hspace="4" vspace="4" border="1" align="right" alt="" src="http://www.blogcdn.com/www.bloggingstocks.com/media/2010/02/gsk-logo-240.jpg" />GlaxoSmithKline (<a href="http://www.dailyfinance.com/quotes/glaxosmithkline-plc/gsk/nys" target="_blank">GSK</a>) announced Thursday that fourth-quarter earnings rocketed 66% thanks to sales of its swine flu vaccine. <a href="http://www.dailyfinance.com/article/glaxosmithkline-4q-profit-up-66-pct/439861/" target="_blank">GSK earned</a> 1.63 billion pounds in the quarter ($2.6 billion) compared to 982 million pounds a year earlier. Excluding restructuring charges, GSK saw profit increase to 1.8 billion pounds, which was slightly above analyst estimates. The company's vaccine sales increased 78% to 1.5 billion pounds, in part due to swine flu vaccine sales. Full-year profits checked in at 5.5 billion pounds, or $8.7 billion.<br />
<br />
All wasn't well with the quarter for GSK. The pharmaceutical firm saw generic competition take a 4% chunk out of its U.S. sales. In addition, GSK announced plans to trim its research and development program, but did not specify how many jobs it would cut.<p><a href="http://www.bloggingstocks.com/2010/02/04/glaxosmithkline-benefits-from-the-flu-during-the-fourth-quarter/" rel="bookmark">Continue reading <em>GlaxoSmithKline Benefits from the Flu During the Fourth Quarter</em></a></p><p style="padding:5px;background:#ddd;border:1px solid #ccc;clear:both;"><a href="http://www.bloggingstocks.com/2010/02/04/glaxosmithkline-benefits-from-the-flu-during-the-fourth-quarter/">GlaxoSmithKline Benefits from the Flu During the Fourth Quarter</a> originally appeared on <a href="http://www.bloggingstocks.com">BloggingStocks</a> on Thu, 04 Feb 2010 10:20:00 EST.  Please see our <a href="http://www.weblogsinc.com/feed-terms/">terms for use of feeds</a>.</p><h6 style="clear: both; padding: 8px 0 0 0; height: 2px; font-size: 1px; border: 0; margin: 0; padding: 0;"></h6><a href="http://www.bloggingstocks.com/2010/02/04/glaxosmithkline-benefits-from-the-flu-during-the-fourth-quarter/" rel="bookmark" title="Permanent link to this entry">Permalink</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/forward/19344709/" title="Send this entry to a friend via email">Email this</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/2010/02/04/glaxosmithkline-benefits-from-the-flu-during-the-fourth-quarter/#comments" title="View reader comments on this entry">Comments</a>]]></description><category>earnings</category><category>featured</category><category>generic drugs</category><category>generic medicine</category><category>GenericDrugs</category><category>GlaxoSmithKline</category><category>GSK</category><category>inthenews</category><category>job cuts</category><dc:creator><![CDATA[Mark Fightmaster]]></dc:creator><pubDate>Thu, 04 Feb 2010 10:20:00 EST</pubDate></item><item><title><![CDATA[Roche sees solid first-half profits]]></title><link>http://www.bloggingstocks.com/2009/07/23/roche-sees-solid-first-half-profits/</link><guid isPermaLink="true">http://www.bloggingstocks.com/2009/07/23/roche-sees-solid-first-half-profits/</guid><comments>http://www.bloggingstocks.com/2009/07/23/roche-sees-solid-first-half-profits/#comments</comments><description><![CDATA[<p>Filed under: <a href="http://www.bloggingstocks.com/category/earnings-reports/" rel="tag">Earnings Reports</a></p><p><img border="1" hspace="4" alt="" vspace="4" align="right" src="http://www.blogcdn.com/www.bloggingstocks.com/media/2009/07/roche.gif" />Bright and early this morning, <a href="http://finance.aol.com/quotes/roche-hldg-ltd-spons/rhhby/nao">Roche Group</a> (OTC: <a href="http://finance.aol.com/quotes/roche-hldg-ltd-spons/rhhby/nao">RHHB</a>) announced <a href="http://www.reuters.com/article/marketsnews/idINLM23313320090723?rpc=33">first-half earnings</a> and upped its annual earnings goal, thanks to impressive sales of Tamiflu. Roche's first-half profit (it only reports earnings twice) dropped 29% to $3.8 billion as the company was hit by costs related to its purchase of Genentech. That said, Roche upped its earnings guidance and forecast double-digit core earnings growth in both 2009 and 2010 -- the earlier forecast called for earnings to stay at 2008 levels.</p><p><a href="http://www.bloggingstocks.com/2009/07/23/roche-sees-solid-first-half-profits/" rel="bookmark">Continue reading <em>Roche sees solid first-half profits</em></a></p><p style="padding:5px;background:#ddd;border:1px solid #ccc;clear:both;"><a href="http://www.bloggingstocks.com/2009/07/23/roche-sees-solid-first-half-profits/">Roche sees solid first-half profits</a> originally appeared on <a href="http://www.bloggingstocks.com">BloggingStocks</a> on Thu, 23 Jul 2009 08:00:00 EST.  Please see our <a href="http://www.weblogsinc.com/feed-terms/">terms for use of feeds</a>.</p><h6 style="clear: both; padding: 8px 0 0 0; height: 2px; font-size: 1px; border: 0; margin: 0; padding: 0;"></h6><a href="http://www.bloggingstocks.com/2009/07/23/roche-sees-solid-first-half-profits/" rel="bookmark" title="Permanent link to this entry">Permalink</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/forward/19107281/" title="Send this entry to a friend via email">Email this</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/2009/07/23/roche-sees-solid-first-half-profits/#comments" title="View reader comments on this entry">Comments</a>]]></description><category>featured</category><category>genentech</category><category>generic drugs</category><category>generic medicine</category><category>pharmaceuticals</category><category>Roche</category><category>swine flu</category><category>tamiflu</category><dc:creator><![CDATA[Mark Fightmaster]]></dc:creator><pubDate>Thu, 23 Jul 2009 08:00:00 EST</pubDate></item><item><title><![CDATA[The dumbing down of the global economy]]></title><link>http://www.bloggingstocks.com/2008/06/02/the-dumbing-down-of-the-global-economy/</link><guid isPermaLink="true">http://www.bloggingstocks.com/2008/06/02/the-dumbing-down-of-the-global-economy/</guid><comments>http://www.bloggingstocks.com/2008/06/02/the-dumbing-down-of-the-global-economy/#comments</comments><description><![CDATA[<p>Filed under: <a href="http://www.bloggingstocks.com/category/economic-data/" rel="tag">Economic Data</a></p><p><img alt="" hspace="4" src="http://www.blogcdn.com/www.bloggingstocks.com/media/2007/12/soldier-iraq-oil.jpg" align="right" vspace="4" border="1" />A graph from the May 2008 issue of Harvard Business Review tells a story about the dumbing down of the global economy.</p>
<p>From an article, <em><a href="http://harvardbusinessonline.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=R0805D&amp;referral=2340">Rebuilding the R&amp;D Engine in Big Pharma</a></em> [subscription required] the graph shows the total shareholder returns for various industries in two time periods: from 1985 to 2000 and from 2001 to 2007. Here are three of the leading sectors from 1985 to 2000 (average annual shareholder returns are in parentheses):</p>
<ul>
    <li>Pharmaceuticals (20.0%) </li>
    <li>Financials (18.8%) </li>
    <li>IT (17.4%) </li>
</ul>
<p>Between 2001 and 2007, three of the leading sectors were:</p>
<ul>
    <li>Energy (15.2%) </li>
    <li>Materials (14.3%) </li>
    <li>Financials (7.0%) </li>
</ul><p><a href="http://www.bloggingstocks.com/2008/06/02/the-dumbing-down-of-the-global-economy/" rel="bookmark">Continue reading <em>The dumbing down of the global economy</em></a></p><p style="padding:5px;background:#ddd;border:1px solid #ccc;clear:both;"><a href="http://www.bloggingstocks.com/2008/06/02/the-dumbing-down-of-the-global-economy/">The dumbing down of the global economy</a> originally appeared on <a href="http://www.bloggingstocks.com">BloggingStocks</a> on Mon, 02 Jun 2008 17:34:00 EST.  Please see our <a href="http://www.weblogsinc.com/feed-terms/">terms for use of feeds</a>.</p><h6 style="clear: both; padding: 8px 0 0 0; height: 2px; font-size: 1px; border: 0; margin: 0; padding: 0;"></h6><a href="http://www.bloggingstocks.com/2008/06/02/the-dumbing-down-of-the-global-economy/" rel="bookmark" title="Permanent link to this entry">Permalink</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/forward/1212919/" title="Send this entry to a friend via email">Email this</a>&nbsp;|&nbsp;<a href="http://www.bloggingstocks.com/2008/06/02/the-dumbing-down-of-the-global-economy/#comments" title="View reader comments on this entry">Comments</a>]]></description><category>biotechnology</category><category>biotechnology stocks</category><category>BiotechnologyStocks</category><category>generic</category><category>generic drugs</category><category>generic medicine</category><category>GenericDrugs</category><category>genericmedicine</category><category>information technology</category><category>InformationTechnology</category><category>manufacturing</category><category>materials</category><category>oil</category><category>pharmaceutical</category><category>pharmaceutical stocks</category><category>pharmaceuticals</category><category>PharmaceuticalStocks</category><category>RD</category><dc:creator><![CDATA[Peter Cohan]]></dc:creator><pubDate>Mon, 02 Jun 2008 17:34:00 EST</pubDate></item></channel></rss>
